The College of American Pathologists (CAP) has released quarterly updates to 14 of its Cancer Protocols, introducing changes that alter breast cancer biomarker reporting and molecular testing for gastrointestinal stromal tumors (GISTs). The revisions are designed to align clinical pathology reporting standards with advances in precision oncology and evolving World Health Organization (WHO) classifications.
Breast Cancer Protocol Updates and Accreditation Mandates
Among the primary modifications, the Breast Phyllodes Tumor protocol is now required for laboratory accreditation when reporting malignant phyllodes tumors, CAP stated in a release. The revised protocol incorporates WHO 6th Edition updates, changes to reporting elements, and updated criteria for cancer staging and surgical margin reporting.
The Q3 release also updates the Breast Biomarker Protocol, adjusting the scoring and reporting criteria for estrogen receptor, progesterone receptor, and HER2, according to the organization. These modifications are intended to foster consistent reporting of critical biomarkers used to guide breast cancer treatment selection and clinical care decisions.
Read more: CAP Updates Cancer Protocols for Breast Biomarkers and GIST Molecular Testing